Донзакимиг

Rec. INN (наименование, зарегистрированное ВОЗ)

2765066-99-5

immunoglobulin G1(VH-CH1-h)-scFv_L-kappa-scFv, anti-[Homo sapiens IL22 (interleukin 22, IL-22, ILTIF, IL-TIF)], anti-[Homo sapiens IL13 (interleukin 13, IL-13)] and anti-[Homo sapiens ALB (albumin, human serum albumin, HAS)], humanized, trispecific, trivalent;
fused G1(VH-CH1-h)-scFv heavy-kappa heavy chain humanized (1-486) [G1(VH-CH1-h) anti-IL22 humanized (1-222) [VH (Homo sapiens IGHV3-23*04 (83.7%) -(IGHD) -IGHJ5*02 (100%), CDR-IMGT [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo sapiens IGHG1*01 CH1-h, G1m17 (CH1 K120 (216) (120-217), hinge 1-5 (218-222)) (120-222)] -11-mer seryl-bis(tetraglycyl-seryl) linker (223-233) -scFv heavy-kappa anti-ALB humanized, scFv-v1 C49 (VH)-C120 (VL) (234-486) [VH (Homo sapiens IGHV3-23*01 (78.6%) -(IGHD) -IGHJ2*01 (93.3%) C49 (277), R120>Q (346) (CDR-IMGT [8.7.15] (259-266.284-290.329-343)) (234-354) -20-mer tetrakis(tetraglycyl-seryl) linker (355-374) -V-KAPPA (Homo sapiens IGKV1-12*01 (86.5%) -IGKJ1*01 (90.9%) C120 (477), CDR-IMGT [7.3.11] (401-407.425-427.464-474)) (375-486)]];
fused L-kappa-scFv heavy-kappa light chain humanized (1'-474') [L-KAPPA anti-IL22 humanized (1’-219’) [V-KAPPA (Homo sapiens IGKV1-9*03 (89.8%) -IGKJ4*01 (100%), CDR-IMGT [6.3.14] (27'-32'.50'-52'.89'-102')) (1'-112') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (158'), V101 (196') (113'-219')] -11-mer seryl-bis(tetraglycyl-seryl) linker (220'-230') -scFv heavy-kappa anti-IL13 humanized, scFv-1 C49 (VH)-C120 (VL) (231'-474') [VH (Homo sapiens IGHV1-69*08 (81.6%) -(IGHD) -IGHJ1*01 (100%), C49 (274), CDR-IMGT [8.8.9] (256'-263'.281'-288'.327'-335')) (231'-346') -20-mer tetrakis(tetraglycyl-seryl) linker (347'-366') -V-KAPPA (Homo sapiens IGKV1-NL1*01 (83.9%) -IGKJ2*01 (91.7%) C120 (465'), CDR-IMGT [6.3.8] (393'-398'.416'-418'.455'-462')) (367'-474')]]; produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, non-glycosylated

Поделиться этой страницей